Disease Areas

Prescribing information for:

FERINJECT^®(ferric carboxymaltose) FILSPARI^®(sparsentan): 200 mg FILSPARI^®(sparsentan): 400 mg AVACOPAN VIFOR VELTASSA^®(patiromer): 8.4 g dose VELTASSA^®(patiromer): 16.8g dose KAPRUVIA^®(difelikefalin)

Nephrology

CSL strives to improve lives of people suffering from kidney disease, through our broad, innovative nephrology portfolio and individualised solutions.

CHRONIC KIDNEY DISEASE-
ASSOCIATED PRURITUS (CKDaP)

YOUR HAEMODIALYSIS PATIENTS MAY BE SUFFERING IN SILENCE WITH CKD‑aP

View CKD-aP

OUR DISEASE AREAS

CKD-associated pruritus (CKD-aP)

UK-DFK-2500038 | Date of preparation: May 2025

Adverse events should be reported. Reporting forms and information for the United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Fresenius Medical Care Renal Pharma, care of Vifor Pharma Ltd.
Tel: +44 1276 853633. E-mail: MedicalInfo_UK@viforpharma.com.